SPP1 Promotes Enzalutamide Resistance and Epithelial-Mesenchymal-Transition Activation in Castration-Resistant Prostate Cancer via PI3K/AKT and ERK1/2 Pathways

<div>High expression of SPP1 in CRPC with bone metastasis. (a) Comparison of SPP1 expression in mCRPC group and PCa group in GSE32269 dataset. (b–d) HCMDB analysis of SPP1 expression level in bone metastasis compared in lymph nodes and posterior peritoneum metastasis. Immunohistochemical (IHC) staining performed to determine the expression of SPP1 in primary PCa (e) and bone metastasis CRPC (f).</div>

Oxidative Medicine and Cellular Longevity

fig2

Figure 2

Figure 2: SPP1 Promotes Enzalutamide Resistance and Epithelial-Mesenchymal-Transition Activation in Castration-Resistant Prostate Cancer via PI3K/AKT and ERK1/2 Pathways 

Figure 2 | SPP1 Promotes Enzalutamide Resistance and Epithelial-Mesenchymal-Transition Activation in Castration-Resistant Prostate Cancer via PI3K/AKT and ERK1/2 Pathways 